IBM Watson is teaming up with Quest Diagnostics and New York City-based Memorial Sloan Kettering Cancer Center to launch a new service: Watson Genomics from Quest Diagnostics, according to Fortune.
Through the service, physicians will be able to send a patient's tumor tissue to Quest Diagnostics for genetic sequencing. IBM Watson will then analyze the genetic alterations in the tissue, and Memorial Sloan Kettering will conduct a research-based analysis through its oncology precision medicine database to determine potential treatment options.
Through the collaboration, the partners hope to give physicians "the ability to create a unique, personalized approach for their patients," according to IBM.